Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $307.65 and traded as high as $319.1455. Genmab A/S shares last traded at $319.1455, with a volume of 3 shares changing hands.
Genmab A/S Trading Up 0.7%
The company has a market capitalization of $21.09 billion, a PE ratio of 13.60 and a beta of 0.88. The business’s fifty day moving average is $307.65 and its two-hundred day moving average is $262.74.
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported $6.46 EPS for the quarter, topping analysts’ consensus estimates of $4.86 by $1.60. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1 billion. Genmab A/S had a return on equity of 23.98% and a net margin of 41.36%.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
- Five stocks we like better than Genmab A/S
- How to Invest in the FAANG Stocks
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- The Significance of Brokerage Rankings in Stock Selection
- Dell and HP Are Raising Prices—And Investors Should Take Note
- How to Choose Top Rated Stocks
- Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
